Ezaki Glico (TSE:2206) just moved beyond snacks into personalized nutrition by partnering with Viome Life Sciences on mRNA HEALTH TRACKER, a gut bacteria mRNA based health service launched for customers in Japan.
For context, Ezaki Glico's share price has eased over the past quarter and year to date, yet the 3-year total shareholder return of 31.66% and 5-year total shareholder return of 27.75% point to a much stronger longer run. As a result, this new personalized nutrition push lands as the stock's recent momentum is fading rather than accelerating.
Scan other gut health and nutrition plays by reviewing the hand picked 9 healthcare AI stocks that link data driven health platforms with consumer focused products.
Bulls see Ezaki Glico using the Viome deal to turn snack brand trust into higher margin health services. Bears point to soft recent returns and a low analyst target. Which story do the current valuation signals back?
Preferred P/E of 48.6x for Ezaki Glico: Is it justified?
At recent prices, Ezaki Glico trades on a P/E of 48.6x, which is high next to many food peers and sits against a share price of ¥5,038 and a one year total return that declined 1.8%.
P/E compares what investors pay today for each unit of current earnings. For a mature food and beverage group like Ezaki Glico, such a rich earnings multiple usually implies the market is assigning sizeable value to future profit growth or to the resilience of its brands rather than to recent profit trends.
The signals here pull in different directions. The stock is flagged as trading at a 46% discount to an estimated future cash flow value of ¥9,332.28 using the SWS DCF model. However, the earnings multiple is described as expensive versus the estimated fair P/E of 28.9x and against both the JP Food industry average of 17.2x and a peer group on 20.1x. Those gaps suggest investors are paying a premium for expected earnings growth relative to sector norms, while the DCF output points to more support from long term cash flows than the P/E alone would indicate.
Across those comparisons, the P/E of 48.6x is described as materially higher than the JP Food industry and peer averages, and also materially above the fair P/E level that regression analysis suggests the market could move towards if sentiment or expectations cool.
Explore the SWS fair ratio for Ezaki Glico.
Result: Price-to-Earnings of 48.6x (OVERVALUED).
Still, Ezaki Glico faces pressure from a share price that has declined 6.1% year to date and trades above a lower analyst target of ¥3,900, which could challenge the upbeat narrative.
Find out about the key risks to this Ezaki Glico narrative .
Another View on Ezaki Glico's Value
Where the P/E points to an expensive Ezaki Glico, the SWS DCF model paints a different picture. On that framework, the stock trades around 46% below an estimated future cash flow value of ¥9,332.28, which frames recent weakness as a potential mispricing rather than pure over optimism.
That spread raises a practical question for you as an investor: Which signal carries more weight in your process, what the market pays for today's earnings or what a cash flow model suggests for the long haul.
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day ( check out Ezaki Glico for example ). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 17 high quality undervalued stocks . If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
Mixed signals or early opportunity? If Ezaki Glico's risk and reward balance interests you, move quickly, review the data, and weigh the 2 key rewards and 3 important warning signs .
Looking for more Ezaki Glico sized ideas?
If Ezaki Glico has sharpened your appetite for opportunity, do not stop here. Broaden your watchlist with focused stock ideas built from consistent screening rules.
-
Target potential long-term compounding with a carefully filtered set of quality opportunities using the 17 high quality undervalued stocks .
-
Strengthen your income stream by scanning for durable cash generators through the 14 dividend fortresses .
-
Prioritise staying power and financial resilience by reviewing the list of solid balance sheet and fundamentals (20 results) .
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include 2206.T .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
